Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 3
1968 2
1969 1
1970 4
1971 4
1972 2
1973 2
1974 1
1975 8
1976 14
1977 13
1978 4
1979 5
1980 2
1981 2
1982 7
1983 6
1984 12
1985 8
1986 6
1987 5
1988 11
1989 5
1990 8
1991 18
1992 6
1993 15
1994 15
1995 18
1996 18
1997 16
1998 12
1999 20
2000 19
2001 15
2002 17
2003 27
2004 18
2005 30
2006 37
2007 31
2008 34
2009 36
2010 28
2011 49
2012 48
2013 54
2014 56
2015 62
2016 61
2017 64
2018 91
2019 71
2020 95
2021 69
2022 71
2023 70
2024 29

Text availability

Article attribute

Article type

Publication date

Search Results

1,340 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Infection following live vaccination"
Page 1
Therapeutic Vaccines for Tuberculosis: An Overview.
Bouzeyen R, Javid B. Bouzeyen R, et al. Front Immunol. 2022 Jun 24;13:878471. doi: 10.3389/fimmu.2022.878471. eCollection 2022. Front Immunol. 2022. PMID: 35812462 Free PMC article. Review.
One modality emerging for TB treatment is therapeutic vaccination. As opposed to preventative vaccination - the aim of which is to prevent getting infected by M. tuberculosis or developing active tuberculosis, the purpose of therapeutic vaccination is …
One modality emerging for TB treatment is therapeutic vaccination. As opposed to preventative vaccination - the aim of which i …
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003).
Rivera L, Biswal S, Sáez-Llorens X, Reynales H, López-Medina E, Borja-Tabora C, Bravo L, Sirivichayakul C, Kosalaraksa P, Martinez Vargas L, Yu D, Watanaveeradej V, Espinoza F, Dietze R, Fernando L, Wickramasinghe P, Duarte MoreiraJr E, Fernando AD, Gunasekera D, Luz K, Venâncioda Cunha R, Rauscher M, Zent O, Liu M, Hoffman E, LeFevre I, Tricou V, Wallace D, Alera M, Borkowski A. Rivera L, et al. Clin Infect Dis. 2022 Aug 24;75(1):107-117. doi: 10.1093/cid/ciab864. Clin Infect Dis. 2022. PMID: 34606595 Free PMC article. Clinical Trial.
BACKGROUND: Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. ...Rates of serious adverse events were 2.9% in TAK-003 group and 3.5% in placebo g …
BACKGROUND: Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clin …
Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults.
Kallás EG, Cintra MAT, Moreira JA, Patiño EG, Braga PE, Tenório JCV, Infante V, Palacios R, de Lacerda MVG, Batista Pereira D, da Fonseca AJ, Gurgel RQ, Coelho IC, Fontes CJF, Marques ETA, Romero GAS, Teixeira MM, Siqueira AM, Barral AMP, Boaventura VS, Ramos F, Elias Júnior E, Cassio de Moraes J, Covas DT, Kalil J, Precioso AR, Whitehead SS, Esteves-Jaramillo A, Shekar T, Lee JJ, Macey J, Kelner SG, Coller BG, Boulos FC, Nogueira ML. Kallás EG, et al. N Engl J Med. 2024 Feb 1;390(5):397-408. doi: 10.1056/NEJMoa2301790. N Engl J Med. 2024. PMID: 38294972 Clinical Trial.
BACKGROUND: Butantan-Dengue Vaccine (Butantan-DV) is an investigational, single-dose, live, attenuated, tetravalent vaccine against dengue disease, but data on its overall efficacy are needed. METHODS: In an ongoing phase 3, double-blind trial in Brazi …
BACKGROUND: Butantan-Dengue Vaccine (Butantan-DV) is an investigational, single-dose, live, attenuated, tetravalent vaccine …
Live attenuated vaccines: Historical successes and current challenges.
Minor PD. Minor PD. Virology. 2015 May;479-480:379-92. doi: 10.1016/j.virol.2015.03.032. Epub 2015 Apr 8. Virology. 2015. PMID: 25864107 Free article. Review.
Live attenuated vaccines against human viral diseases have been amongst the most successful cost effective interventions in medical history. ...The derivation of the vaccines used has in general not been purely rational except in the sense that it has involve …
Live attenuated vaccines against human viral diseases have been amongst the most successful cost effective interventions in me …
EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021.
Jansen MHA, Rondaan C, Legger GE, Minden K, Uziel Y, Toplak N, Maritsi D, van den Berg L, Berbers GAM, Bruijning P, Egert Y, Normand C, Bijl M, Foster HE, Koné-Paut I, Wouters C, Ravelli A, Elkayam O, Wulffraat NM, Heijstek MW. Jansen MHA, et al. Ann Rheum Dis. 2023 Jan;82(1):35-47. doi: 10.1136/annrheumdis-2022-222574. Epub 2022 Jun 20. Ann Rheum Dis. 2023. PMID: 35725297
Non-live vaccines can be safely given to immunosuppressed pedAIIRD patients. ...Live-attenuated vaccines should be avoided in immunosuppressed patients. ...
Non-live vaccines can be safely given to immunosuppressed pedAIIRD patients. ...Live-attenuated vaccines should …
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Biswal S, Borja-Tabora C, Martinez Vargas L, Velásquez H, Theresa Alera M, Sierra V, Johana Rodriguez-Arenales E, Yu D, Wickramasinghe VP, Duarte Moreira E Jr, Fernando AD, Gunasekera D, Kosalaraksa P, Espinoza F, López-Medina E, Bravo L, Tuboi S, Hutagalung Y, Garbes P, Escudero I, Rauscher M, Bizjajeva S, LeFevre I, Borkowski A, Saez-Llorens X, Wallace D; TIDES study group. Biswal S, et al. Lancet. 2020 May 2;395(10234):1423-1433. doi: 10.1016/S0140-6736(20)30414-1. Epub 2020 Mar 17. Lancet. 2020. PMID: 32197105 Clinical Trial.
We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4-16 years. METHODS: We present data up to 18 months post-vaccination from an ongoing phase 3, randomised, do …
We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healt …
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.
Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, Morgan RL, Fry AM. Grohskopf LA, et al. MMWR Recomm Rep. 2022 Aug 26;71(1):1-28. doi: 10.15585/mmwr.rr7101a1. MMWR Recomm Rep. 2022. PMID: 36006864 Free PMC article.
Inactivated influenza vaccines (IIV4s), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. ...THIRD, RECOMMENDATIONS FOR VACCINATION OF ADULTS AGED 65 YEARS HAVE BEEN MODIFIED. ACIP …
Inactivated influenza vaccines (IIV4s), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine …
A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R, Widenmaier R, Lecrenier N. Parikh R, et al. Expert Rev Vaccines. 2021 Sep;20(9):1065-1075. doi: 10.1080/14760584.2021.1956906. Epub 2021 Sep 1. Expert Rev Vaccines. 2021. PMID: 34311643 Review.
AREAS COVERED: National recommendations from ten countries (Austria, Canada, the Czech Republic, Germany, Ireland, Italy, Spain, the Netherlands, the UK and the USA) are summarized under the following seven topics: HZ vaccine preference, age group recommendations, c …
AREAS COVERED: National recommendations from ten countries (Austria, Canada, the Czech Republic, Germany, Ireland, Italy, Spain, the Netherl …
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F, Zhuang C, Chu K, Zhang L, Zhao H, Huang S, Su Y, Lin H, Yang C, Jiang H, Zang X, Liu D, Pan H, Hu Y, Liu X, Chen Q, Song Q, Quan J, Huang Z, Zhong G, Chen J, Han J, Sun H, Cui L, Li J, Chen Y, Zhang T, Ye X, Li C, Wu T, Zhang J, Xia NS. Zhu F, et al. Lancet Respir Med. 2022 Aug;10(8):749-760. doi: 10.1016/S2213-2600(22)00131-X. Epub 2022 May 26. Lancet Respir Med. 2022. PMID: 35644168 Free PMC article. Clinical Trial.
METHODS: We did double-blind, randomised, placebo-controlled phase 1 and 2 trials, followed by a phase 2 extension trial, at a single centre in Jiangsu, China. ...To avoid cross-contamination during administration, vaccine and placebo recipients were …
METHODS: We did double-blind, randomised, placebo-controlled phase 1 and 2 trials, followed by a phase 2 extension trial …
Varicella vaccines.
Flatt A, Breuer J. Flatt A, et al. Br Med Bull. 2012 Sep;103(1):115-27. doi: 10.1093/bmb/lds019. Epub 2012 Aug 2. Br Med Bull. 2012. PMID: 22859715 Review.
The use of live-attenuated varicella vaccine to reduce the burden of these diseases has been established in many countries for a number of years. ...Live VZV vaccines are safe and effective at protecting against disease caused by VZV. ...
The use of live-attenuated varicella vaccine to reduce the burden of these diseases has been established in many countries for …
1,340 results